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To the Editor,
We wish to thank Honore et  al. [1] for their interest in 
our article [2] and raising a caveat concerning the possi-
ble effect of renal replacement therapy (RRT) on proen-
kephalin (P-PENK) and neutrophil gelatinase-associated 
lipocalin (P-NGAL) levels in plasma. As suggested by 
Honore et al., this confounding could lead to an underes-
timation of the association of early P-PENK and P-NGAL 
levels with mortality so that if true, the association 
described in our article could in reality be even stronger. 
However, as the removal of solutes by RRT is affected 
also by factors other than molecular weight (such as 
charge, albumin binding capability, the type of membrane 
and RRT technique used) whether a molecule is removed 
from plasma by RRT and to which extent is difficult to 
predict and should be empirically tested. One small study 
performed in septic patients with AKI did not detect 
NGAL (or KIM-1) in the dialysate of continuous RRT [3], 
but data on the effect of RRT on plasma levels of the bio-
markers in our study are mostly lacking.
In our study the time of onset of RRT was recorded 
in 17/22 patients and only 7 patients (5% of all patients 
included in our study) had RRT performed within 24 h of 
study baseline. Considering the small number of patients 
in the study who had RRT within 24  h of baseline, we 
believe that this would not affect the overall results.
Specifically for patients undergoing continuous RRT, 
using P-PENK, P-NGAL or any other biomarker that 
could be removed from circulation by RRT as a risk 
marker might lead to an underestimation of risk and 
should be interpreted with caution. We completely agree 
with Honore et al. that studies assessing the performance 
of prognostic biomarkers in this specific patient group 
are lacking and should be targeted for future studies.
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